Androgen Deprivation Therapy As Adjuvant/neoadjuvant to Radiotherapy for High-risk Localised and Locally Advanced Prostate Cancer: Recent Developments

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Oct 20

PMID 22009028

Citations 19

Authors

H Payne

M Mason

Affiliations

Soon will be listed here.

Abstract

Androgen deprivation therapy (ADT) has traditionally formed the mainstay of treatment for advanced/metastatic prostate cancer (PCa); however, it is now also having an increasingly important role in earlier stages of disease. Indeed, in patients with locally advanced or high-risk localised disease, the addition of neoadjuvant and adjuvant hormone therapy is now considered the standard of care for those men treated with radical radiotherapy. Although luteinising hormone-releasing hormone (LHRH) agonists have been used for many years as ADT, they may be associated with clinical flare and testosterone breakthrough. Newer hormonal agents continue to be developed, such as gonadotropin-releasing hormone antagonists, which reduce testosterone and prostate-specific antigen levels more rapidly than LHRH agonists, without testosterone flare. This review examines ADT use in combination with radiotherapy to improve outcomes in localised or locally advanced disease, and examines some of the latest developments in hormonal therapy for PCa.

Citing Articles

Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study.

Yi Z, Li H, Li M, Hu J, Cai Z, Liu Z World J Urol. 2024; 42(1):581.

PMID: 39419868 DOI: 10.1007/s00345-024-05286-6.

Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.

van Genderen M, Kneppers J, Zaalberg A, Bekers E, Bergman A, Zwart W NPJ Syst Biol Appl. 2024; 10(1):20.

PMID: 38383542 PMC: 10881528. DOI: 10.1038/s41540-024-00344-6.

Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer.

Zetrini A, Lip H, Abbasi A, Alradwan I, Ahmed T, He C Research (Wash D C). 2023; 6:0247.

PMID: 37795337 PMC: 10546607. DOI: 10.34133/research.0247.

Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer.

Mou Z, Spencer J, Knight B, John J, McCullagh P, McGrath J Front Oncol. 2022; 12:914078.

PMID: 36033512 PMC: 9413154. DOI: 10.3389/fonc.2022.914078.

Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men.

Katongole P, Sande O, Reynolds S, Joloba M, Kajumbula H, Kalungi S Oncol Ther. 2022; 10(1):185-193.

PMID: 35128628 PMC: 9098749. DOI: 10.1007/s40487-022-00184-6.

References

McLeod D, Iversen P, See W, Morris T, Armstrong J, Wirth M . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006; 97(2):247-54. DOI: 10.1111/j.1464-410X.2005.06051.x. View

Hanks G, Pajak T, Porter A, Grignon D, Brereton H, Venkatesan V . Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21(21):3972-8. DOI: 10.1200/JCO.2003.11.023. View

Horwitz E, Bae K, Hanks G, Porter A, Grignon D, Brereton H . Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26(15):2497-504. DOI: 10.1200/JCO.2007.14.9021. View

Denham J, Steigler A, Lamb D, Joseph D, Turner S, Matthews J . Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011; 12(5):451-9. DOI: 10.1016/S1470-2045(11)70063-8. View

Sasagawa I, Kubota Y, Nakada T, Suzuki H, Hirano J, Sugano O . Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate. Int Urol Nephrol. 1999; 30(6):745-53. DOI: 10.1007/BF02564863. View

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V . [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp. 2011; 35(10):565-79. DOI: 10.1016/j.acuro.2011.03.011. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Widmark A, Klepp O, Solberg A, Damber J, Angelsen A, Fransson P . Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2008; 373(9660):301-8. DOI: 10.1016/S0140-6736(08)61815-2. View

Bolla M, de Reijke T, van Tienhoven G, van den Bergh A, Oddens J, Poortmans P . Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360(24):2516-27. DOI: 10.1056/NEJMoa0810095. View

10.

Weckermann D, Harzmann R . Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol. 2004; 46(3):279-83. DOI: 10.1016/j.eururo.2004.05.006. View

11.

Boccon-Gibod L, van der Meulen E, Persson B . An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol. 2011; 3(3):127-40. PMC: 3159401. DOI: 10.1177/1756287211414457. View

12.

Roach 3rd M, Bae K, Speight J, Wolkov H, Rubin P, Lee R . Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26(4):585-91. DOI: 10.1200/JCO.2007.13.9881. View

13.

Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P . Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys. 2009; 76(1):23-30. DOI: 10.1016/j.ijrobp.2009.01.030. View

14.

Pilepich M, Winter K, Lawton C, Krisch R, Wolkov H, Movsas B . Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61(5):1285-90. DOI: 10.1016/j.ijrobp.2004.08.047. View

15.

Boustead G, Edwards S . Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU Int. 2007; 99(6):1383-9. DOI: 10.1111/j.1464-410X.2007.06802.x. View

16.

Zelefsky M, Leibel S, Burman C, Kutcher G, Harrison A, Happersett L . Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1994; 29(4):755-61. DOI: 10.1016/0360-3016(94)90563-0. View

17.

Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View

18.

van Poppel H, Nilsson S . Testosterone surge: rationale for gonadotropin-releasing hormone blockers?. Urology. 2008; 71(6):1001-6. DOI: 10.1016/j.urology.2007.12.070. View

19.

Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A . Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003; 57(4):915-28. DOI: 10.1016/s0360-3016(03)00632-1. View

20.

Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Crawford E . Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2009; 57(5):836-42. DOI: 10.1016/j.eururo.2009.11.029. View